Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo
| Autor: | E. Van Strijen, H. Mattie, B R Sekh, M. L. Van Ogtrop |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
medicine.drug_class Cefepime Antibiotics Ceftazidime Mice Inbred Strains Microbial Sensitivity Tests Biology medicine.disease_cause Microbiology Mice Pharmacokinetics In vivo Escherichia coli medicine Animals Pharmacology (medical) Escherichia coli Infections Escherichia coli infection Pharmacology In vitro Cephalosporins Infectious Diseases Research Article medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 36:2439-2443 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.36.11.2439 |
| Popis: | The efficacies of cefepime and ceftazidime in an experimental Escherichia coli infection in granulocytopenic mice were related to their in vitro activities and their pharmacokinetic profiles. Cefepime had a higher intrinsic activity in vitro than ceftazidime, and it had a different pharmacokinetic profile, resulting in higher peak concentrations in plasma and a longer elimination half-life. To predict the antibacterial efficacy in vivo on the basis of in vitro activity and pharmacokinetics, we applied a mathematical model in which the in vitro effect is expressed as the difference in growth rate between control cultures and cultures grown in the presence of the antibiotic (ER), whereas the in vivo effect is given by the difference in the number of CFU between controls and antibiotic-treated animals (EN). The integral of ER over time, called ERt, was calculated by using in vivo concentrations. A significant linear relationship was found between EN and ERt for different doses at various times up to 4 h after administration, although the slope of this relationship was slightly but significantly less for cefepime (0.44) than for ceftazidime (0.59). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|